Pfenex, Inc. awarded $143.5 million HHS contract
This funding will advance the development of the Px563L protective antigen vaccine for anthrax.
This contract will fund base activity related to the vaccine's manufacturing and facilitate Phase 1A clinical trials, with the options of agreements or extensions for further stages of clinical studies.
"This contract for the development of Px563L offers the potential for a dramatic improvement in the rapid production of large amounts of a high-value, stable recombinant anthrax vaccine for the U.S. government," Pfenex CEO Bertrand Liang said. "The ability to meet articulated medical countermeasure needs, including fulfillment of the requirements of the Strategic National Stockpile, is a key goal in the program."
The company states the potential exists for the completed vaccines to be part of the National Strategic Stockpile through a procurement contract once it has completed development and necessary clinical testing.
Phenex is focused on the development and manufacture of biosimilar therapeutics and proteins.